Literature DB >> 33717406

Vigabatrin-associated Reversible MRI Abnormalities in an Infant with Tuberous Sclerosis.

Joseph Franklin Craft1, Agustin M Cardenas2.   

Abstract

Vigabatrin therapy is commonly used in infants diagnosed with tuberous sclerosis complex, particularly in the setting of epilepsy. Utilization of vigabatrin can result in bilateral and symmetric abnormal sequence changes within the deep brain matter and brainstem on magnetic resonance imaging. These abnormalities occur predominantly in infancy, are reversible, and can be asymptomatic or result in symptomatic clinical manifestations. We present a case with classic neuroimaging findings. Familiarity with these findings can prevent unnecessary follow up tests or studies and the cost of continuing or discontinuing vigabatrin therapy should be weighed heavily against the potential manifestation of extrapyramidal symptoms. Copyright Journal of Radiology Case Reports.

Entities:  

Keywords:  MRI; Pediatric Neuroimaging; Tuberous Sclerosis Complex; VABAM; Vigabatrin; Vigabatrin Toxicity; Vigabatrin-associated brain abnormalities

Mesh:

Substances:

Year:  2021        PMID: 33717406      PMCID: PMC7942967          DOI: 10.3941/jrcr.v15i2.3918

Source DB:  PubMed          Journal:  J Radiol Case Rep        ISSN: 1943-0922


  7 in total

1.  Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms.

Authors:  Aphrodite Dracopoulos; Elysa Widjaja; Charles Raybaud; Carol A Westall; O Carter Snead
Journal:  Epilepsia       Date:  2010-04-02       Impact factor: 5.864

2.  Vigabatrin-related magnetic resonance imaging abnormalities in an infant with tuberous sclerosis complex and infantile spasms.

Authors:  David T Hsieh; Elizabeth A Thiele
Journal:  J Pediatr       Date:  2012-09-12       Impact factor: 4.406

3.  Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent.

Authors:  Shaun A Hussain; Jackie Tsao; Menglu Li; Madeline D Schwarz; Raymond Zhou; Joyce Y Wu; Noriko Salamon; Raman Sankar
Journal:  Epilepsia       Date:  2017-02-23       Impact factor: 5.864

4.  Cerebral MRI abnormalities associated with vigabatrin therapy.

Authors:  Phillip L Pearl; Louis G Vezina; Russell P Saneto; Robert McCarter; Elizabeth Molloy-Wells; Ari Heffron; Stacey Trzcinski; William M McClintock; Joan A Conry; Nancy J Elling; Howard P Goodkin; Marcio Sotero de Menezes; Raymond Ferri; Elizabeth Gilles; Nadja Kadom; William D Gaillard
Journal:  Epilepsia       Date:  2008-09-08       Impact factor: 5.864

5.  Vigabatrin-induced MRI changes associated with extrapyramidal symptoms in a child with infantile spasms.

Authors:  Valeria Schonstedt; Ximena Stecher; Viviana Venegas; Claudio Silva
Journal:  Neuroradiol J       Date:  2015-08-25

6.  Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms?

Authors:  Patricia Dill; Alexandre N Datta; Peter Weber; Jacques Schneider
Journal:  Eur J Paediatr Neurol       Date:  2012-11-27       Impact factor: 3.140

7.  An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms.

Authors:  Choong Yi Fong; John P Osborne; Stuart W Edwards; Cheryl Hemingway; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Rachel Kneen; Marcus Likeman; Andrew L Lux; Santosh R Mordekar; Velayutham Murugan; Richard W Newton; Michael Pike; Michael Quinn; Stefan Spinty; Grace Vassallo; Christopher M Verity; Andrea Whitney; Finbar J K O'Callaghan
Journal:  Dev Med Child Neurol       Date:  2013-06-22       Impact factor: 5.449

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.